Anzeige
Mehr »
Login
Sonntag, 19.09.2021 Börsentäglich über 12.000 News von 674 internationalen Medien
Rennen um begehrtesten KLIMA-ROHSTOFF beginnt! Holt sich Nobel Resources die Pole-Position?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0M84G ISIN: SE0002190926 Ticker-Symbol: 2I9 
Frankfurt
17.09.21
08:11 Uhr
0,402 Euro
+0,032
+8,65 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
KAROLINSKA DEVELOPMENT AB Chart 1 Jahr
5-Tage-Chart
KAROLINSKA DEVELOPMENT AB 5-Tage-Chart

Aktuelle News zur KAROLINSKA DEVELOPMENT Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
09.09.Karolinska Development AB (publ): Karolinska Development's portfolio company OssDsign includes first patient to a clinical trial of the synthetic bone graft OssDsign Catalyst175STOCKHOLM, SWEDEN - September 9, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the portfolio company OssDsign AB has included the first patient to the clinical trial...
► Artikel lesen
19.08.Karolinska Development AB (publ): Interim Report - January-June 20214
KAROLINSKA DEVELOPMENT Aktie jetzt für 0€ handeln
16.08.Karolinska Development AB (publ): Karolinska Development's portfolio company OssDsign launches the synthetic bone graft OssDsign Catalyst on the U.S. market278STOCKHOLM, SWEDEN - August 16, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the portfolio company OssDsign AB has launched OssDsign Catalyst in the U.S. The product...
► Artikel lesen
12.08.Karolinska Development AB (publ): Karolinska Development's portfolio company Aprea Therapeutics announces that FDA has issued a clinical hold on lymphoid malignancy program292STOCKHOLM, SWEDEN - August 12, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the US Food and Drug Administration (FDA) has issued a clinical hold for Aprea Therapeutics...
► Artikel lesen
22.07.Karolinska Development AB (publ): Karolinska Development's portfolio company Aprea Therapeutics announces positive Phase 2 results for eprenetapopt269STOCKHOLM SWEDEN - July 22, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the portfolio company Aprea Therapeutics has reported positive results from a Phase 2 trial...
► Artikel lesen
15.07.Karolinska Development AB (publ): Karolinska Development's portfolio company Modus Therapeutics raises SEK 33 million through an oversubscribed issue and now prepares for listing259STOCKHOLM, SWEDEN - July 15, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the portfolio company Modus Therapeutics has completed an oversubscribed issue of units (113%...
► Artikel lesen
14.07.Karolinska Development AB (publ): Karolinska Development's portfolio company Umecrine Cognition raises capital through a successful share issue255STOCKHOLM, SWEDEN - July 14, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the portfolio company Umecrine Cognition has carried out a directed new share issue of SEK...
► Artikel lesen
07.07.Karolinska Development AB (publ): Karolinska Development's portfolio company Promimic receives market clearance for HAnano Surface in orthopedic oncology in collaboration with Onkos Surgical205STOCKHOLM, SWEDEN - July 7, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the portfolio company Promimic has received a shared 501(k) clearance from the U.S. Food and...
► Artikel lesen
07.07.Karolinska Development AB (publ): Karolinska Development sells its holding in Lipidor AB and receives a net of SEK 4 million276STOCKHOLM, SWEDEN - July 7, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the company has sold its entire holding in the listed portfolio company Lipidor AB. In total...
► Artikel lesen
17.06.Karolinska Development AB (publ): Karolinska Development expands its portfolio through new investment in AnaCardio1
17.06.Karolinska Development AB (publ): Karolinska Development increases book value of Dilafor that is indirectly owned via KDev Investments AB by SEK 450 million1
17.06.Karolinska Development AB (publ): Karolinska Development's portfolio company Aprea Therapeutics lead candidate drug eprenetapopt reaches primary efficacy endpoint in combination therapy of acute myeloid leukemia368STOCKHOLM, SWEDEN - June 17, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company Aprea Therapeutics has reported positive outcomes in an ongoing Phase...
► Artikel lesen
15.06.Karolinska Development AB (publ): Karolinska Development's portfolio company Modus Therapeutics and Imperial College London to conduct clinical study of sevuparin in severe malaria228STOCKHOLM, SWEDEN - June 15, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company Modus Therapeutics has entered into a collaboration agreement with Imperial...
► Artikel lesen
11.06.Karolinska Development AB (publ): Karolinska Development's portfolio company Promimic evaluates the possibility of a listing on Nasdaq First North Growth ...-
10.06.Karolinska Development AB (publ): Karolinska Development's portfolio company Biosergen raises SEK 50 million through a successful unit offering and prepares for IPO397STOCKHOLM, SWEDEN - June 10, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company Biosergen has completed a successful and fully subscribed unit offering...
► Artikel lesen
01.06.Karolinska Development AB (publ): Karolinska Development's portfolio company Dilafor presents positive results from a phase 2b study of tafoxiparin1
21.05.Karolinska Development AB (publ): Karolinska Development's portfolio company Umecrine Cognition initiates preparations for listing on Nasdaq First North Growth Market243STOCKHOLM, SWEDEN 21 May 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company Umecrine Cognition is preparing a listing on Nasdaq First North Growth Market...
► Artikel lesen
12.05.Karolinska Development AB (publ): Karolinska Development's portfolio company OssDsign raises SEK 270 million through an oversubscribed rights issue318STOCKHOLM, SWEDEN - May 12, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company OssDsign completed a successful rights issue of shares with preferential...
► Artikel lesen
05.05.Karolinska Development AB (publ): Karolinska Development's Annual General Meeting 20212
29.04.Karolinska Development AB (publ): Interim Report - January-March 2021-
Seite:  Weiter >>
33 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1